Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.13 USD
-0.93 (-7.12%)
Updated May 17, 2024 04:00 PM ET
After-Market: $12.08 -0.05 (-0.41%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 161 - 163 ( 163 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are initiating coverage of Enanta Pharmaceuticals, Inc. with a Buy rating
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH Weekly Newsletter: NASH News Flow From JP Morgan Healthcare Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Agenda for Our First Annual NASH Investor Conference on April 3 in NY
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E